Eczacıbasi Momentum

Established in 2019 as a corporate venture capital fund, Eczacıbaşı Momentum aims to strengthen the start-up ecosystem by investing in high-impact start-ups and technologies. The purpose of the fund is to invest in start-ups that are active in wellbeing, consumption, and home-living, that shape the new normal of modern life, and that have an international perspective. Eczacıbaşı Momentum's focus, in this context, is new technologies and business models. In addition to gain financial returns, start-ups also benefit from the knowledge and business relations of the Eczacıbaşı Group.

Berktug Incekas

Head of VC Investments

8 past transactions

ecomercek

Pre Seed Round in 2023
Ecomercek is an online marketplace focused on selling environmentally safe cosmetics, skincare, personal hygiene, and home care products. The company evaluates and scores these products based on their environmental and health effects, ensuring an impartial and transparent assessment process. By providing content consultation prior to product releases, Ecomercek collaborates with businesses to enhance consumer awareness about sustainable choices. Their platform enables customers to easily find and purchase products that are beneficial for both personal health and the environment, promoting a holistic approach to product evaluation.

ecomercek

Seed Round in 2022
Ecomercek is an online marketplace focused on selling environmentally safe cosmetics, skincare, personal hygiene, and home care products. The company evaluates and scores these products based on their environmental and health effects, ensuring an impartial and transparent assessment process. By providing content consultation prior to product releases, Ecomercek collaborates with businesses to enhance consumer awareness about sustainable choices. Their platform enables customers to easily find and purchase products that are beneficial for both personal health and the environment, promoting a holistic approach to product evaluation.

RS Research

Series A in 2021
RS Research is a clinical-stage biotechnology company focused on developing nanomedicines for cancer treatment. Based in Istanbul, Turkey, it has developed a proprietary Sagitta drug-delivery platform that enables targeted chemotherapies across multiple indications. The company advances a portfolio of nanomedicine candidates through preclinical and clinical stages, with its lead program RS-0139 studied in Phase I oncology trials and supported by a GMP-certified production facility for clinical batch drug candidates. RS Research collaborates with international partners on co-development projects and offers ancillary services such as preclinical absorption, distribution, metabolism, and excretion testing, bioanalytical method development and validation, impurity and metabolite analysis, stability testing, toxicology studies, and patent-related due diligence and drafting support. The business aims to deliver targeted therapies with improved therapeutic indices through its nanocarrier technology and partnerships.

Newlab

Venture Round in 2021
Newlab is a collaborative community designed to support entrepreneurs, engineers, and innovators in addressing significant global challenges through transformative technologies. It provides an interdisciplinary workspace that includes resident spaces, on-site product development facilities, and specialized programming. By fostering collaboration among its members, Newlab enables the exploration and creation of innovative solutions across various fields, including robotics, artificial intelligence, and material science. The organization connects its members with city agencies, venture capitalists, domain experts, and corporate partners, ensuring that entrepreneurs have the necessary resources and support to advance their projects and define the future of technology. Through its focus on sustainable solutions, Newlab is dedicated to making a positive impact on health, the environment, media, urban development, and infrastructure.

Virasoft

Series A in 2021
Founded in 2015, Virasoft specializes in digital pathology software development. Its platform streamlines diagnostic processes using AI-powered algorithms for decision support, telepathology services, and case management applications. Serving tens of institutions globally, it annually assists hundreds of thousands of patients.

Kunduz

Seed Round in 2021
Kunduz is an education-focused company that offers a mobile application designed to provide students with prompt assistance for academic queries. By integrating a tutor platform with proprietary artificial intelligence, Kunduz allows users to take a picture of a problem and receive answers within ten minutes. This approach combines the accessibility of technology with personalized support, setting it apart from traditional tutoring resources. The service is affordably priced, making high-quality study help available for as little as $15 per month. Established after participating in Y Combinator's Summer Batch in 2018, Kunduz is now expanding its services globally, aiming to deliver efficient and cost-effective educational support to students, academics, and professionals.

Figopara

Series A in 2020
Figopara is a platform that enables businesses to optimize cash flow by facilitating early payment of invoices. It connects buyers and suppliers, allowing the latter to receive payments earlier than due dates, while the former benefit from extended payment terms.

Vagustim

Pre Seed Round in 2019
Vagustim is a developer of innovative wearable neuromodulation devices that utilize electrical stimulation of the vagus nerve in both ears. The company focuses on non-invasive auricular vagus nerve stimulation, which activates the parasympathetic nervous system to balance the autonomic nervous system. By collecting data and adjusting stimulation parameters, Vagustim's devices aim to aid individuals in managing stress-related disorders and enhancing overall health. The company's commitment to harnessing the potential of Vagus Nerve Stimulation reflects its goal to improve health outcomes globally through advanced medical solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.